Literature DB >> 31595682

Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry - A New Zealand perspective of use in 2018.

Rui Shen Ong1, Diana C Kappatos1, Sarah G G Russell1, Helen A Poulsen1, Samuel D Banister2,3, Roy R Gerona4, Michelle Glass5, Cameron S Johnson6, Mary-Jane McCarthy1.   

Abstract

We describe the validation of a method for the simultaneous analysis of 29 synthetic cannabinoids (SCs) and metabolites, 4 amphetamines, and 2 cannabinoids in human whole blood. This method enables one analysis to cover what previously required multiple analyses for these classic and novel drugs-of-abuse with diverse physicochemical properties. The scope of targeted analytes was based on the most prevalent drugs-of-abuse and SCs encountered at the New Zealand border in 2017 and included parent compounds and metabolites belonging to the indole and indazole carboxamide, quinolinyl indole carboxylate, and naphthoylindole classifications. Samples were prepared by supported-liquid-extraction (SLE) followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis with positive electrospray ionization (ESI). The method was validated with respect to selectivity, matrix effects, process efficiency, sensitivity, repeatability, extract stability, and carryover for qualitative confirmation. Linearity as well as accuracy and precision data at target decision concentrations were also evaluated. The limits of detection and confirmation ranged from 0.1 to 6.0 ng/mL and 1.0 to 6.0 ng/mL, respectively. The described method was successfully applied to the analysis of 564 ante- and post-mortem blood samples in 2018. There were 132 cases (23%) with positive findings of at least one SC, with the five most commonly detected SCs being AMB-FUBINACA and/or acid (61%), 5F-ADB and/or acid (40%), ADB-FUBINACA (11%), 5F-MDMB-PICA acid (6%), and MDMB-FUBINACA acid (6%). The results also demonstrate the predominant presence of metabolites at higher levels than the unchanged parent SCs in blood, highlighting the need to maintain forensic screening methods capable of the simultaneous detection of both parent compounds and metabolites.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Amphetamine-type stimulants (ATS); New Zealand; new psychoactive substances (NPS); supported-liquid-extraction (SLE); synthetic cannabinoids

Year:  2019        PMID: 31595682     DOI: 10.1002/dta.2697

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  7 in total

Review 1.  Detection of the Synthetic Cannabinoids AB-CHMINACA, ADB-CHMINACA, MDMB-CHMICA, and 5F-MDMB-PINACA in Biological Matrices: A Systematic Review.

Authors:  Elisabet Navarro-Tapia; Jana Codina; Víctor José Villanueva-Blasco; Óscar García-Algar; Vicente Andreu-Fernández
Journal:  Biology (Basel)       Date:  2022-05-23

2.  Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice.

Authors:  Grant C Glatfelter; John S Partilla; Michael H Baumann
Journal:  Neuropsychopharmacology       Date:  2021-11-20       Impact factor: 8.294

3.  Fatal intoxication with new synthetic cannabinoids 5F-MDMB-PICA and 4F-MDMB-BINACA-parent compounds and metabolite identification in blood, urine and cerebrospinal fluid.

Authors:  Bogdan Tokarczyk; Agnieszka Jurczyk; Justyna Krupińska; Piotr Adamowicz
Journal:  Forensic Sci Med Pathol       Date:  2022-06-14       Impact factor: 2.456

4.  Development and validation of a rapid LC-MS/MS method for the detection of 182 novel psychoactive substances in whole blood.

Authors:  Arianna Giorgetti; Rossella Barone; Guido Pelletti; Marco Garagnani; Jennifer Pascali; Belal Haschimi; Volker Auwärter
Journal:  Drug Test Anal       Date:  2021-10-21       Impact factor: 3.234

Review 5.  [Testing for cannabis and synthetic cannabinoids in human specimens].

Authors:  Pascal Kintz
Journal:  Bull Acad Natl Med       Date:  2020-04-16       Impact factor: 0.144

Review 6.  Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications.

Authors:  Carolina Lobato-Freitas; Andreia Machado Brito-da-Costa; Ricardo Jorge Dinis-Oliveira; Helena Carmo; Félix Carvalho; João Pedro Silva; Diana Dias-da-Silva
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-25

7.  Effects of synthetic cannabinoids on psychomotor, sensory and cognitive functions relevant for safe driving.

Authors:  Vasco Orazietti; Giuseppe Basile; Raffaele Giorgetti; Arianna Giorgetti
Journal:  Front Psychiatry       Date:  2022-09-26       Impact factor: 5.435

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.